KFDA to brace for expediting evaluation process of new biopharmaceuticals

Despite Korean pharmaceutical firms's efforts to accelerate their R&D studies of new biopharmaceuticals, there are growing concerns that the insufficient number of eligible assessment specialists might become one of the major roadblocks for timely development of breakthrough biopharmaceuticals, according to the Korea Food and Drug Administration.

According to the KFDA, the number of consulta...